We narrowed to 49,426 results for: prot

#100852-AAV1

Ready-to-use AAV1 particles produced from pAAV.CAG.Flex.NES-jRGECO1a.WPRE.SV40 (#100852). In addition to the viral particles, you will also receive purified pAAV.CAG.Flex.NES-jRGECO1a.WPRE.SV40 plasmid DNA. CAG-driven, Cre-dependent jRGECO1a calcium sensor. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Dana et al eLife. 2016 Mar 24;5. pii: e12727. doi:

July 23, 2018

Academic Institutions and Nonprofits only

#100850-AAV1

Ready-to-use AAV1 particles produced from pAAV.Syn.Flex.NES-jRCaMP1b.WPRE.SV40 (#100850). In addition to the viral particles, you will also receive purified pAAV.Syn.Flex.NES-jRCaMP1b.WPRE.SV40 plasmid DNA. Syn-driven, Cre-dependent NES-jRCaMP1b calcium sensor. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Dana et al eLife. 2016 Mar 24;5. pii: e12727. doi:

May 11, 2018

Academic Institutions and Nonprofits only

#218877-AAV1

Ready-to-use AAV1 particles produced from pGP-AAV-syn-flex-iGABASnFR2-WPRE (#218877). In addition to the viral particles, you will also receive purified pGP-AAV-syn-flex-iGABASnFR2-WPRE plasmid DNA. Syn-driven, Cre-dependent expression of the improved GABA sensor iGABASnFR2 (positive change in fluorescence). These AAV preparations are suitable purity for injection into animals.

GENIE Project

Kolb et al bioRxiv 2025.03.25.644953

Sept. 27, 2024

Academic Institutions and Nonprofits only

#22222-AAV9

Ready-to-use AAV9 particles produced from AAV-FLEX-Arch-GFP (#22222). In addition to the viral particles, you will also receive purified AAV-FLEX-Arch-GFP plasmid DNA. CAG-driven cre-dependent Arch-GFP expression for optogenetic neural inhibition. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Chow et al Nature. 2010 Jan 7. 463(7277):98-102.

Feb. 20, 2018

Academic Institutions and Nonprofits only

#218877-AAV5

Ready-to-use AAV5 particles produced from pGP-AAV-syn-flex-iGABASnFR2-WPRE (#218877). In addition to the viral particles, you will also receive purified pGP-AAV-syn-flex-iGABASnFR2-WPRE plasmid DNA. Syn-driven, Cre-dependent expression of the improved GABA sensor iGABASnFR2 (positive change in fluorescence). These AAV preparations are suitable purity for injection into animals.

GENIE Project

Kolb et al bioRxiv 2025.03.25.644953

Sept. 27, 2024

Academic Institutions and Nonprofits only

#100851-AAV1

Ready-to-use AAV1 particles produced from pAAV.Syn.NES-jRCaMP1b.WPRE.SV40 (#100851). In addition to the viral particles, you will also receive purified pAAV.Syn.NES-jRCaMP1b.WPRE.SV40 plasmid DNA. Syn-driven jRCaMP1b calcium sensor. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Dana et al eLife. 2016 Mar 24;5. pii: e12727. doi:

April 13, 2018

Academic Institutions and Nonprofits only

#100849-AAV1

Ready-to-use AAV1 particles produced from pAAV.CAG.Flex.NES-jRCaMP1b.WPRE.SV40 (#100849). In addition to the viral particles, you will also receive purified pAAV.CAG.Flex.NES-jRCaMP1b.WPRE.SV40 plasmid DNA. CAG-driven, Cre-dependent NES-jRCaMP1b calcium sensor. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Dana et al eLife. 2016 Mar 24;5. pii: e12727. doi:

May 11, 2018

Academic Institutions and Nonprofits only

#100846-AAV1

Ready-to-use AAV1 particles produced from pAAV.CAG.Flex.NES-jRCaMP1a.WPRE.SV40 (#100846). In addition to the viral particles, you will also receive purified pAAV.CAG.Flex.NES-jRCaMP1a.WPRE.SV40 plasmid DNA. CAG-driven, Cre-dependent jRCaMP1a calcium sensor. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Dana et al eLife. 2016 Mar 24;5. pii: e12727. doi:

May 11, 2018

Academic Institutions and Nonprofits only

#117382-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV-hSyn1-eYFP (#117382). In addition to the viral particles, you will also receive purified pAAV-hSyn1-eYFP plasmid DNA. hSyn-driven eYFP expression. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Viviana Gradinaru

Challis et al Nat Protoc. 2019 Feb;14(2):379-414. doi:

Jan. 6, 2022

Academic Institutions and Nonprofits only

#117383-AAV1

Ready-to-use AAV1 particles produced from pAAV-TRE-DIO-eYFP (#117383). In addition to the viral particles, you will also receive purified pAAV-TRE-DIO-eYFP plasmid DNA. Tet-inducible, Cre-dependent eYFP expression. These AAV preparations are suitable purity for injection into animals.

Viviana Gradinaru

Challis et al Nat Protoc. 2019 Feb;14(2):379-414. doi:

Jan. 6, 2022

Academic Institutions and Nonprofits only

#117382-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-hSyn1-eYFP (#117382). In addition to the viral particles, you will also receive purified pAAV-hSyn1-eYFP plasmid DNA. hSyn-driven eYFP expression. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Viviana Gradinaru

Challis et al Nat Protoc. 2019 Feb;14(2):379-414. doi:

Oct. 18, 2021

Academic Institutions and Nonprofits only

#218876-AAV5

Ready-to-use AAV5 particles produced from pGP-AAV-syn-iGABASnFR2(no bind)-WPRE (#218876). In addition to the viral particles, you will also receive purified pGP-AAV-syn-iGABASnFR2(no bind)-WPRE plasmid DNA. Syn-driven expression of the improved GABA sensor control iGABASnFR2(no bind) (no change in fluorescence). These AAV preparations are suitable purity for injection into animals.

GENIE Project

Kolb et al bioRxiv 2025.03.25.644953

Sept. 27, 2024

Academic Institutions and Nonprofits only

#22222-AAV1

Ready-to-use AAV1 particles produced from AAV-FLEX-Arch-GFP (#22222). In addition to the viral particles, you will also receive purified AAV-FLEX-Arch-GFP plasmid DNA. CAG-driven cre-dependent Arch-GFP expression for optogenetic neural inhibition. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Chow et al Nature. 2010 Jan 7. 463(7277):98-102.

Feb. 21, 2018

Academic Institutions and Nonprofits only

#218876-AAV1

Ready-to-use AAV1 particles produced from pGP-AAV-syn-iGABASnFR2(no bind)-WPRE (#218876). In addition to the viral particles, you will also receive purified pGP-AAV-syn-iGABASnFR2(no bind)-WPRE plasmid DNA. Syn-driven expression of the improved GABA sensor control iGABASnFR2(no bind) (no change in fluorescence). These AAV preparations are suitable purity for injection into animals.

GENIE Project

Kolb et al bioRxiv 2025.03.25.644953

Sept. 27, 2024

Academic Institutions and Nonprofits only

#104055-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-CAG-eYFP (#104055). In addition to the viral particles, you will also receive purified pAAV-CAG-eYFP plasmid DNA. CAG-driven eYFP expression control. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Viviana Gradinaru

Challis et al Nat Protoc. 2019 Feb;14(2):379-414. doi:

Jan. 6, 2022

Academic Institutions and Nonprofits only

#218873-AAV5

Ready-to-use AAV5 particles produced from pGP-AAV-GFAP-iGABASnFR2(no bind)-WPRE (#218873). In addition to the viral particles, you will also receive purified pGP-AAV-GFAP-iGABASnFR2(no bind)-WPRE plasmid DNA. GFAP-driven expression of the improved GABA sensor control iGABASnFR2(no bind) (no change in fluorescence). These AAV preparations are suitable purity for injection into animals.

GENIE Project

Kolb et al bioRxiv 2025.03.25.644953

Sept. 27, 2024

Academic Institutions and Nonprofits only

#104055-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV-CAG-eYFP (#104055). In addition to the viral particles, you will also receive purified pAAV-CAG-eYFP plasmid DNA. CAG-driven eYFP expression control. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Viviana Gradinaru

Challis et al Nat Protoc. 2019 Feb;14(2):379-414. doi:

June 13, 2023

Academic Institutions and Nonprofits only

#218873-AAV1

Ready-to-use AAV1 particles produced from pGP-AAV-GFAP-iGABASnFR2(no bind)-WPRE (#218873). In addition to the viral particles, you will also receive purified pGP-AAV-GFAP-iGABASnFR2(no bind)-WPRE plasmid DNA. GFAP-driven expression of the improved GABA sensor control iGABASnFR2(no bind) (no change in fluorescence). These AAV preparations are suitable purity for injection into animals.

GENIE Project

Kolb et al bioRxiv 2025.03.25.644953

Sept. 27, 2024

Academic Institutions and Nonprofits only

#45580-AAV5

Ready-to-use AAV5 particles produced from pAAV-flex-taCasp3-TEVp (#45580). In addition to the viral particles, you will also receive purified pAAV-flex-taCasp3-TEVp plasmid DNA. EF1a-driven, Cre-dependent, bicicstronic expression of designer pro-taCasp3 and TEVp. These AAV preparations are suitable purity for injection into animals.

Nirao Shah, Jim Wells

Yang et al Cell. 2013 May 9;153(4):896-909. doi: 10

Sept. 25, 2020

Academic Institutions and Nonprofits only

#104061-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV-CAG-NLS-GFP (#104061). In addition to the viral particles, you will also receive purified pAAV-CAG-NLS-GFP plasmid DNA. CAG-driven NLS-GFP expression. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Viviana Gradinaru

Challis et al Nat Protoc. 2019 Feb;14(2):379-414. doi:

March 5, 2019

Academic Institutions and Nonprofits only